Insight

Insights,

| Stacey Gilbert, MPH, MBA - Director, Precision Medicine

FDA Proposes Down-Classification of Oncology Companion Diagnostics: A Q&A on Precision Medicine

Insights,

| Marc Samuels, JD, MPH - Chief Executive Officer

2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption

Insights,

| Ashis Kumar Das, MD, MPH, PhD - Director

What HEOR Information Does CMS Need for Drug Price Negotiations Under the IRA?

Insights,

| Alicia Silver, MPP - Vice President, Emerging Therapies

Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care

Insights,

| Ashis Kumar Das, MD, MPH, PhD - Director

What is the Inflation Reduction Act (IRA)? A New Era of Medicare Drug Price Negotiations

Insights,

What Clinical Information Does CMS Need for Drug Price Negotiations Under the IRA?

Insights,

| Ashis Kumar Das, MD, MPH, PhD - Director

Real-World Effectiveness vs Clinical Trial Efficacy in Medicare

Insights,

| Ashis Kumar Das, MD, MPH, PhD - Director

Why is Medicare Data Central to IRA Negotiations?

Insights,

| Tyler Seville, MPA - Associate Director

The Unintended Consequences of Drug Pricing Policies on Orphan Drug Development